{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:08Z","timestamp":1790040308850,"version":"4.0.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.molmed.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:09:53Z","timestamp":1671754193000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dupuytren's disease: a localised and accessible human fibrotic disorder"],"prefix":"10.1016","volume":"29","author":[{"given":"Thomas B.","family":"Layton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9579-9411","authenticated-orcid":false,"given":"Jagdeep","family":"Nanchahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2022.12.001_bb0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bmj.332.7538.397","article-title":"Dupuytren's contracture unfolded","volume":"332","author":"Townley","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2022.12.001_bb0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0749-0712(21)00900-8","article-title":"Diagnosis and indications for surgical treatment","volume":"7","author":"Smith","year":"1991","journal-title":"Hand Clin."},{"key":"10.1016\/j.molmed.2022.12.001_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.12688\/f1000research.17779.1","article-title":"Recent advances in the understanding of Dupuytren's disease","volume":"8","author":"Layton","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.molmed.2022.12.001_bb0020","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1302\/2633-1462.311.BJO-2022-0103.R2","article-title":"Cost-effectiveness of adalimumab for early-stage Dupuytren's disease: an early economic evaluation based on a randomised controlled trial and individual patient simulation model","volume":"3","author":"Dakin","year":"2022","journal-title":"Bone Joint Open"},{"key":"10.1016\/j.molmed.2022.12.001_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1753193414535720","article-title":"Genetic and environmental influences in Dupuytren's disease: a study of 30,330 Danish twin pairs","volume":"40","author":"Larsen","year":"2015","journal-title":"J. Hand Surg. Eur."},{"key":"10.1016\/j.molmed.2022.12.001_bb0030","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jhsa.2013.03.036","article-title":"The impact of Dupuytren disease on patient activity and quality of life","volume":"38","author":"Wilburn","year":"2013","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12891-016-1200-y","article-title":"Systematic review of non-surgical treatments for early Dupuytren's disease","volume":"17","author":"Ball","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.molmed.2022.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhsa.2005.03.005","article-title":"A retrospective review of the management of Dupuytren's nodules","volume":"30","author":"Reilly","year":"2005","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.12.001_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-immunol-032712-095937","article-title":"The immunology of fibrosis","volume":"31","author":"Wick","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2022.12.001_bb0065","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","article-title":"Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease","volume":"16","author":"Mora","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2022.12.001_bb0070","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1073\/pnas.1607896113","article-title":"Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need","volume":"113","author":"Nanchahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2022.12.001_bb0075","doi-asserted-by":"crossref","first-page":"E928","DOI":"10.1073\/pnas.1301100110","article-title":"Unraveling the signaling pathways promoting fibrosis in Dupuytren\u2019s disease reveals TNF as a therapeutic target","volume":"110","author":"Verjee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2022.12.001_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13069-016-0046-0","article-title":"Matrix and cell phenotype differences in Dupuytren's disease","volume":"9","author":"van Beuge","year":"2016","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.molmed.2022.12.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158101","article-title":"Meta-analysis of genome-wide association studies and network analysis-based integration with gene expression data identify new suggestive loci and unravel a Wnt-centric network associated with Dupuytren's disease","volume":"11","author":"Becker","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2022.12.001_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1101029","article-title":"Wnt signaling and Dupuytren's disease","volume":"365","author":"Dolmans","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.12.001_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/pgmj.2004.027425","article-title":"Clinical associations of Dupuytren's disease","volume":"81","author":"Hart","year":"2005","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.molmed.2022.12.001_bb0100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jhsa.2005.09.018","article-title":"The heritability of Dupuytren's disease: familial aggregation and its clinical significance","volume":"31","author":"Hindocha","year":"2006","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0895-4356(99)00145-6","article-title":"Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study","volume":"53","author":"Gudmundsson","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1302\/0301-620X.45B4.709","article-title":"The genetic factor in Dupuytren's disease","volume":"45","author":"Ling","year":"1963","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.molmed.2022.12.001_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1302\/0301-620X.84B2.0840211","article-title":"Genetic susceptibility in Dupuytren's disease. TGF-beta1 polymorphisms and Dupuytren's disease","volume":"84","author":"Bayat","year":"2002","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.molmed.2022.12.001_bb0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ajhg.2017.08.006","article-title":"A Genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis","volume":"101","author":"Ng","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2022.12.001_bb0125","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41467-020-16264-y","article-title":"Cellular census of human fibrosis defines functionally distinct stromal cell types and states","volume":"11","author":"Layton","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2022.12.001_bb0130","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1089\/ten.tea.2009.0739","article-title":"Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury","volume":"16","author":"Matsushima","year":"2010","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.molmed.2022.12.001_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2021.02.003","article-title":"A common SNP risk variant MT1-MMP causative for Dupuytren's disease has a specific defect in collagenolytic activity","volume":"97","author":"Itoh","year":"2021","journal-title":"Matrix Biol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0140","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jid.2016.03.036","article-title":"Fibroblast-derived MMP-14 regulates collagen homeostasis in adult skin","volume":"136","author":"Zigrino","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0145","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1302\/0301-620X.80B5.0800907","article-title":"Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor","volume":"80","author":"Hutchinson","year":"1998","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.molmed.2022.12.001_bb0150","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jhsa.2008.04.002","article-title":"Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease","volume":"33","author":"Johnston","year":"2008","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0155","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.02.001","article-title":"MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblast-mediated contraction","volume":"1822","author":"Wilkinson","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2022.12.001_bb0160","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jhsa.2009.08.005","article-title":"Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture","volume":"34","author":"Verjee","year":"2009","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0165","first-page":"10","article-title":"Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture","volume":"1","author":"Satish","year":"2008","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.molmed.2022.12.001_bb0170","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/mt.2016.109","article-title":"Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis","volume":"24","author":"Zhao","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2022.12.001_bb0175","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/path.1427","article-title":"The myofibroblast in wound healing and fibrocontractive diseases","volume":"200","author":"Gabbiani","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jcp.22167","article-title":"Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells","volume":"224","author":"Verjee","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0190","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/17531934211050214","article-title":"Echogenicity of Dupuytren's nodules is correlated to myofibroblast load and nodule hardness","volume":"47","author":"Molenkamp","year":"2022","journal-title":"J. Hand Surg. Eur."},{"key":"10.1016\/j.molmed.2022.12.001_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2022.12.001_bb0200","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jid.2021.05.030","article-title":"Deciphering mesenchymal drivers of human Dupuytren's disease at single-cell level","volume":"142","author":"Dobie","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0205","doi-asserted-by":"crossref","first-page":"20753","DOI":"10.1073\/pnas.2004281117","article-title":"Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP\/EP300","volume":"117","author":"Williams","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2022.12.001_bb0210","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1038\/ncomms12260","article-title":"Genetic lineage tracing defines myofibroblast origin and function in the injured heart","volume":"7","author":"Kanisicak","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2022.12.001_bb0215","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1755-1536-5-S1-S5","article-title":"The myofibroblast, multiple origins for major roles in normal and pathological tissue repair","volume":"5","author":"Micallef","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.molmed.2022.12.001_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1681.2011.05531.x","article-title":"Pivotal role of pericytes in kidney fibrosis","volume":"38","author":"Kida","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0225","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36865","article-title":"Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response","volume":"7","author":"Li","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.molmed.2022.12.001_bb0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2011.02.001","article-title":"Epithelial\u2013mesenchymal transition in chronic liver disease: fibrogenesis or escape from death?","volume":"55","author":"Pinzani","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0235","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2019.02.049","article-title":"Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure","volume":"73","author":"Nagaraju","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0240","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/scd.2011.0140","article-title":"Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy","volume":"21","author":"Iqbal","year":"2012","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.molmed.2022.12.001_bb0245","article-title":"Embryonic stem cell-like population in Dupuytren's disease expresses components of the renin\u2013angiotensin system","volume":"5","author":"On","year":"2017","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"10.1016\/j.molmed.2022.12.001_bb0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40610-016-0045-3","article-title":"Connective tissue degeneration: mechanisms of palmar fascia degeneration (Dupuytren's disease)","volume":"2","author":"Karkampouna","year":"2016","journal-title":"Curr. Mol. Biol. Rep."},{"key":"10.1016\/j.molmed.2022.12.001_bb0255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nmeth.3834","article-title":"Measuring cell-generated forces: a guide to the available tools","volume":"13","author":"Polacheck","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.molmed.2022.12.001_bb0260","article-title":"Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states","volume":"9","author":"Layton","year":"2020","journal-title":"Biol. Open"},{"key":"10.1016\/j.molmed.2022.12.001_bb0265","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/jid.2013.219","article-title":"Isometric contraction of Dupuytren's myofibroblasts is inhibited by blocking intercellular junctions","volume":"133","author":"Verhoekx","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0270","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0275","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bbadis.2013.02.007","article-title":"Tissue mechanics and fibrosis","volume":"1832","author":"Wells","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2022.12.001_bb0280","first-page":"2911","article-title":"Micro-mechanical characterization of lung tissue using atomic force microscopy","volume":"54","author":"Liu","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.molmed.2022.12.001_bb0285","doi-asserted-by":"crossref","first-page":"L344","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146243","article-title":"Myofibroblast YAP\/TAZ activation is a key step in organ fibrogenesis","volume":"7","author":"He","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2022.12.001_bb0295","doi-asserted-by":"crossref","first-page":"C277","DOI":"10.1152\/ajpcell.00205.2016","article-title":"TAZ activation drives fibroblast spheroid growth, expression of profibrotic paracrine signals, and context-dependent ECM gene expression","volume":"312","author":"Jorgenson","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0300","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.ajpath.2015.08.011","article-title":"YAP1 is a driver of myofibroblast differentiation in normal and diseased fibroblasts","volume":"185","author":"Piersma","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0305","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1091\/mbc.e04-05-0386","article-title":"Myofibroblast development is characterized by specific cell-cell adherens junctions","volume":"15","author":"Hinz","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.molmed.2022.12.001_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-0712(21)00436-4","article-title":"Cellular structure and biology of Dupuytren's disease","volume":"15","author":"Tomasek","year":"1999","journal-title":"Hand Clin."},{"key":"10.1016\/j.molmed.2022.12.001_bb0315","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jb\/mvi054","article-title":"Alterations in the extracellular matrix proteoglycan profile in Dupuytren's contracture affect the palmar fascia","volume":"137","author":"Kozma","year":"2005","journal-title":"J. Biochem."},{"key":"10.1016\/j.molmed.2022.12.001_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0363-5023(78)80112-9","article-title":"Pathogenesis of Dupuytren's contracture: a correlative clinical-pathological study","volume":"3","author":"Chiu","year":"1978","journal-title":"J. Hand Surg."},{"key":"10.1016\/j.molmed.2022.12.001_bb0325","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/01.SAP.0000069066.35253.B3","article-title":"Microarray gene analysis and expression profiles of Dupuytren's contracture","volume":"50","author":"Pan","year":"2003","journal-title":"Ann. Plast. Surg."},{"key":"10.1016\/j.molmed.2022.12.001_bb0330","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.PRS.0000081462.40448.49","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease","volume":"112","author":"Ulrich","year":"2003","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.molmed.2022.12.001_bb0335","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urology.2004.04.006","article-title":"Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture","volume":"64","author":"Qian","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.molmed.2022.12.001_bb0340","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.yexcr.2009.07.015","article-title":"Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells","volume":"315","author":"Vi","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.molmed.2022.12.001_bb0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000163879","article-title":"Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix","volume":"62","author":"Berndt","year":"1994","journal-title":"Pathobiology"},{"key":"10.1016\/j.molmed.2022.12.001_bb0350","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jhsa.2008.09.017","article-title":"Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes","volume":"34","author":"Shih","year":"2009","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0355","first-page":"59","article-title":"RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease","volume":"8","author":"Riester","year":"2015","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.molmed.2022.12.001_bb0360","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/ncomms4485","article-title":"Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction","volume":"5","author":"Sun","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2022.12.001_bb0365","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ndt\/gfab163","article-title":"Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis","volume":"37","author":"Sparding","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.molmed.2022.12.001_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175200","article-title":"Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease","volume":"12","author":"Fenton","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2022.12.001_bb0375","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0363-5023(96)80102-X","article-title":"The role of transforming growth factor beta in Dupuytren's disease","volume":"21","author":"Badalamente","year":"1996","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0380","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jcp.46.5.425","article-title":"Abnormal growth factor and cytokine expression in Dupuytren's contracture","volume":"46","author":"Baird","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0385","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/BF02389692","article-title":"TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin","volume":"27","author":"Berndt","year":"1995","journal-title":"Histochem. J."},{"key":"10.1016\/j.molmed.2022.12.001_bb0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2474-12-113","article-title":"Reversal of TGF-beta1 stimulation of alpha-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts","volume":"12","author":"Satish","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.molmed.2022.12.001_bb0395","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-beta: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0400","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/2000656X.2016.1140054","article-title":"Characterisation of the inflammatory response in Dupuytren's disease","volume":"50","author":"Mayerl","year":"2016","journal-title":"J. Plast. Surg. Hand Surg."},{"key":"10.1016\/j.molmed.2022.12.001_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay0370","article-title":"Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis","volume":"5","author":"Izadi","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2022.12.001_bb0410","doi-asserted-by":"crossref","first-page":"E407","DOI":"10.1016\/S2665-9913(22)00093-5","article-title":"Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"4","author":"Nanchahal","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.molmed.2022.12.001_bb0415","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ebiom.2018.06.022","article-title":"Anti-tumour necrosis factor therapy for Dupuytren's disease: a randomised dose response proof of concept Phase 2a clinical trial","volume":"33","author":"Nanchahal","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2022.12.001_bb0420","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jhsa.2015.10.027","article-title":"Clusters in short-term disease course in participants with primary Dupuytren disease","volume":"41","author":"Lanting","year":"2016","journal-title":"J. Hand Surg. Am."},{"key":"10.1016\/j.molmed.2022.12.001_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz8272","article-title":"Attenuation of Dupuytren's fibrosis via targeting of the STAT1 modulated IL-13R\u03b11 response","volume":"6","author":"Akbar","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2022.12.001_bb0430","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrd.2015.16","article-title":"Single-cell analysis tools for drug discovery and development","volume":"15","author":"Heath","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2022.12.001_bb0435","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120336119","article-title":"A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: importance in human fibrotic disease","volume":"119","author":"Layton","year":"2022","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422003136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422003136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:27:04Z","timestamp":1761463624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491422003136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1471491422003136"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2022.12.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupuytren's disease: a localised and accessible human fibrotic disorder","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}